Dengvaxia, Sanofi’s vaccine for dengue fever, has been burdened with further negative scrutiny after the FDA’s vaccine advisory panel passed mixed judgements on its efficacy and safety in adults and children with the disease.
The agency’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) decided that Sanofi’s vaccine was not effective in preventing the disease in adult patients aged between nine and 45 living in endemic regions who have been previously diagnosed with dengue, with seven votes to six and one abstention.
